Half-life is one of the most cited and least understood concepts in peptide research discussions. It appears in almost every pillar article on this site because it is genuinely important—the duration of a compound’s activity shapes everything from dosing frequency to the pharmacological rationale for choosing one compound over another. But it is also routinely misapplied, leading to both overconfident dosing decisions and flawed comparisons between compounds.
This guide explains what half-life actually means pharmacologically, how it determines dosing intervals and steady-state concentrations, how it applies specifically to research peptides, why the half-life values cited for many compounds are imprecise or context-dependent, and how community dosing conventions relate—and sometimes fail to relate—to the pharmacokinetic principles that should inform them.
Table of Contents
- What Half-Life Actually Means
- Elimination, Distribution, and Why There Are Multiple Half-Lives
- Dosing Intervals, Accumulation, and Steady State
- Peptide Half-Lives: Why They Are Short and What That Means
- How Route of Administration Changes Effective Half-Life
- Half-Life Reference: Compounds Covered on This Site
- Community Dosing Conventions vs. Pharmacokinetic Rationale
- Half-Life Extension Strategies: DAC, PEGylation, and Analogs
- Frequently Asked Questions
What Half-Life Actually Means
A drug’s half-life (t½) is the time required for its plasma concentration to fall by 50%. If a compound has a half-life of 2 hours and its initial plasma concentration after injection is 100 units, then after 2 hours the concentration is approximately 50 units; after 4 hours, approximately 25 units; after 6 hours, approximately 12.5 units; and so on. Each successive half-life reduces the remaining concentration by half.
Plain English
Half-life is how long it takes for half the drug to leave your bloodstream. A 2-hour half-life means the amount halves every 2 hours: 100 → 50 → 25 → 12.5. After about 4–5 half-lives, the compound is essentially gone.
Three practical rules that follow from this exponential decay pattern:
After 1 half-life: 50% of the compound remains. After 2 half-lives: 25% remains. After 4–5 half-lives: approximately 94–97% has been eliminated—the compound is functionally cleared from the system for most purposes. This 4–5 half-life rule is the standard used in pharmacology to define when a compound is essentially eliminated.
The flip side of this rule is equally important and discussed further below: it also takes 4–5 half-lives of regular dosing for a compound to reach steady-state plasma concentration—the stable level where the rate of elimination equals the rate of administration.
Elimination, Distribution, and Why There Are Multiple Half-Lives
The simple half-life curve shown above represents first-order elimination—a single-compartment model where the compound is uniformly distributed and eliminated at a rate proportional to its concentration. This is an idealization. Real drug pharmacokinetics often show two or more distinct phases, each with its own apparent half-life.
The Two-Phase Concentration Curve
After intravenous injection, many compounds show a rapid initial concentration decrease followed by a slower, more gradual decline. These two phases represent: the distribution phase (alpha phase)—the compound moving from plasma into peripheral tissues—and the elimination phase (beta phase)—the compound being metabolized and excreted. The half-lives associated with these phases (t½α and t½β) are quite different: the distribution half-life may be minutes; the elimination half-life hours or days.
When a paper reports a compound’s “half-life,” it is typically reporting the terminal elimination half-life (beta phase)—the slower phase that governs how long the compound persists in the system. This is usually the more clinically relevant value for dosing interval calculations. However, for compounds that produce rapid-onset pharmacological effects (like VIP’s vasodilatory effect), the distribution phase and the initial peak concentration matter more than the elimination half-life for understanding the time course of activity.
Peptide-Specific Elimination Mechanisms
Most research peptides are eliminated through peptidase cleavage—enzymatic degradation of peptide bonds in plasma, tissues, and at receptor surfaces. The peptidases responsible vary by peptide: VIP is primarily degraded by neutral endopeptidase (NEP/CD10) and dipeptidyl peptidase IV (DPP-IV). GLP-1 receptor agonists like semaglutide are resistant to DPP-IV degradation, which is why they have longer half-lives than native GLP-1. Growth hormone-releasing peptides are susceptible to a range of plasma peptidases, producing the short half-lives characteristic of this class.
Renal filtration also contributes to elimination for small peptides—the kidney filters molecules below approximately 30,000–50,000 g/mol by glomerular filtration. Most research peptides (typically under 5,000 g/mol) are below this threshold and subject to renal filtration and tubular degradation. Patients with impaired renal function may show altered pharmacokinetics for peptide compounds, though this is rarely addressed in research peptide literature.
Dosing Intervals, Accumulation, and Steady State
The relationship between half-life and dosing interval determines whether a compound accumulates in the body over repeated doses, and what the eventual steady-state concentration looks like.
Plain English
How often you dose depends on half-life. Dose more frequently than the compound can clear, and it builds up in your system. Dose too infrequently, and levels drop to zero between doses. The goal is usually to find the sweet spot where levels stay in a useful range.
The Accumulation Principle
If you dose a compound more frequently than once per elimination period (4–5 half-lives), the compound accumulates—each dose adds to what remains from the previous dose, and the plasma concentration gradually rises over successive doses until it reaches steady state. At steady state, the average concentration remains stable because the amount eliminated per dosing interval exactly equals the amount administered.
For compounds with short half-lives—which includes most research peptides—each dose is largely eliminated before the next one. There is minimal accumulation, which means plasma concentrations do not build up to a stable sustained level the way they would with a compound dosed at an interval shorter than its elimination period. This is pharmacologically important: a compound with a 30-minute half-life, dosed once daily, achieves a brief peak concentration and then is essentially gone for 23+ hours. The biological effects must either occur during that brief window or persist through receptor- or downstream-pathway-mediated mechanisms that outlast the compound’s plasma presence.
Peak vs. Trough: When Timing Matters
For some compounds and applications, the peak concentration achieved after each dose is the pharmacologically relevant parameter—the compound needs to reach a certain concentration threshold to produce its effect, and the duration above that threshold determines the effective dose window. For other compounds and applications, sustained receptor occupancy—maintaining a concentration above the minimum effective level as continuously as possible—matters more. These two scenarios call for different dosing strategies.
Pulsatile dosing (intermittent peaks with low trough levels) is actually the physiologically appropriate pattern for growth hormone-releasing peptides, because this mirrors the natural pulsatile pattern of endogenous GH secretion. Continuous infusion of GHRH analogs can paradoxically desensitize the pituitary receptors. This is a pharmacological rationale for once or twice daily dosing of GH secretagogues—not just convention.
Peptide Half-Lives: Why They Are Short and What That Means
Most research peptides have short plasma half-lives—typically measured in minutes rather than hours. This is not an accident or a flaw; it is a property of the peptide chemistry. Endogenous peptides that serve as signaling molecules are designed by evolution to be short-lived: precise temporal control of signaling requires that the signal ends promptly when the peptide is cleared. The plasma peptidases that rapidly degrade these compounds are the machinery of that temporal control.
The consequences for research applications are significant. A compound with a 10-minute intravenous half-life achieves peak activity briefly after injection and declines rapidly. The pharmacological question—whether this brief exposure is sufficient to produce the sustained downstream biological effects attributed to the compound—is often not addressed in the preclinical literature, which tends to focus on what a compound does rather than how long the exposure needs to last to achieve it.
For human clinical applications, the short half-life problem has driven three major development strategies: sustained delivery formulations (patches, implants, infusion pumps), chemical modifications that resist peptidase degradation (discussed below), and receptor agonist analogs that are structurally distinct from the natural peptide while retaining receptor activity. The GLP-1 receptor agonists are the most commercially successful example of the third strategy—semaglutide is so structurally modified relative to native GLP-1 that it has a half-life of approximately one week compared to native GLP-1’s 2-minute half-life.
How Route of Administration Changes Effective Half-Life
The half-life values published in research papers are typically determined by IV injection—the route that produces the most complete and rapid absorption, giving the cleanest pharmacokinetic profile for analysis. Subcutaneous injection produces a different concentration-time profile that modifies the effective half-life in a practically important way.
After subcutaneous injection, the compound must first be absorbed from the injection depot into the bloodstream—a process that takes time and produces a slower, lower peak concentration compared to IV injection. This absorption delay (characterized by the time to peak concentration, or Tmax) extends the duration of activity: the compound reaches lower peak concentrations but spends more time above a given threshold concentration than an IV bolus would.
The effective half-life from subcutaneous injection is therefore longer than the IV half-life for the same compound—sometimes substantially so. This is why subcutaneous injection is preferred over IV injection for most research peptide applications: it achieves a more physiologically reasonable concentration-time profile with less severe peaks and more sustained activity, despite the peptide having a short intrinsic IV half-life.
The caveat: the absorption kinetics from subcutaneous injection vary with injection site, injection depth, local blood flow, and the volume and concentration of the injected solution. Pharmacokinetic data from SC injection in formal studies may not precisely replicate what occurs in individual self-experimentation contexts.
Half-Life Reference: Compounds Covered on This Site
Context note: Half-life values vary by route of administration, species studied, and measurement methodology. Values listed as “IV” reflect intravenous administration data; “SC” reflects subcutaneous where available. For most research peptides, precise human SC pharmacokinetic data does not exist. Treat all values as approximate reference points, not precise parameters.
| Compound | Approximate Half-Life | Route | Notes |
|---|---|---|---|
| VIP | 1–2 minutes | IV | Rapidly degraded by NEP and DPP-IV; among the shortest half-lives of any compound on this site |
| Native GLP-1 | 1–2 minutes | IV | DPP-IV degrades rapidly; basis for DPP-IV-resistant analog development |
| Ipamorelin | ~2 hours | IV/SC (estimated) | Longer than GHRP-2/6 due to structural modifications; data primarily from animal studies |
| GHRP-2 / GHRP-6 | 15–60 minutes | IV/SC | Short; drives the frequent (3×/day) dosing convention in community protocols |
| CJC-1295 (no DAC) | ~30 minutes | SC (estimated) | Short; typically co-administered with ipamorelin to leverage the longer ipamorelin window |
| CJC-1295 with DAC | 6–8 days | SC | DAC (Drug Affinity Complex) binds to albumin; dramatically extends half-life; once or twice weekly dosing |
| Sermorelin | ~10–20 minutes | SC/IV | Very short; used daily or divided doses; pulsatile pattern considered appropriate for GH axis |
| Hexarelin | ~55–70 minutes | IV | Longer than most GHRPs; human PK data exists from clinical studies |
| BPC-157 | Not formally characterized in humans | SC/oral (animal) | No human PK data published; animal estimates suggest relatively rapid clearance; oral bioavailability data is limited |
| TB-500 | Not formally characterized | SC (animal) | No human PK data; some community protocols use once or twice weekly dosing extrapolated from animal studies |
| Thymosin Alpha-1 | ~2 hours | SC (human) | Among the better-characterized compounds; human PK data from clinical trials; twice weekly SC dosing used in approved protocols |
| Semaglutide | ~7 days | SC (human) | DPP-IV resistant by design; albumin binding; once-weekly approved dosing schedule; steady state reached after ~4–5 weeks |
| Tirzepatide | ~5 days | SC (human) | Once-weekly dosing; fatty acid conjugation for albumin binding; well-characterized human PK |
| MK-677 | ~24 hours | Oral | Small molecule GHS-R1a agonist; not a peptide; oral bioavailability enables once-daily dosing; human PK well-characterized from trials |
Community Dosing Conventions vs. Pharmacokinetic Rationale
Community dosing conventions for research peptides have evolved through a combination of extrapolation from animal study doses, comparison to clinical trial protocols where they exist, and self-experimentation tradition passed among early users. The relationship between these conventions and pharmacokinetically derived optimal dosing is variable—sometimes well-aligned, sometimes not.
Where Community Conventions Are Pharmacologically Reasonable
The once or twice daily dosing of CJC-1295 (no DAC) with ipamorelin is pharmacologically defensible. Both compounds have short half-lives; dosing them together at the same time allows the brief GH pulse from CJC-1295 and the somewhat longer window from ipamorelin to overlap. The fasting context for GH secretagogue administration—often 2+ hours post-meal—reflects the real effect of insulin on GH secretion. The timing around sleep capitalizes on the natural nocturnal GH pulse. These conventions reflect reasonable extrapolation from what is known about GH axis pharmacology.
Where Community Conventions Lack Pharmacokinetic Basis
The most common pharmacokinetic disconnect in community dosing is the assumption that more frequent dosing of a short-half-life compound produces proportionally more sustained effect. A compound with a 10-minute IV half-life, dosed once versus twice daily, produces two brief pulses of activity instead of one—but no sustained coverage between doses. Whether two brief pulses per day produce meaningfully different downstream effects than one depends on the specific pharmacology, and this question is rarely addressed in the preclinical literature for most research peptides.
BPC-157’s dosing conventions illustrate this uncertainty particularly clearly. The compound has no published human pharmacokinetic data. Community protocols range from once daily to twice daily, subcutaneous or oral, at various doses. The basis for these conventions is primarily extrapolation from rodent study doses (with imprecise allometric scaling) and forum tradition. They may approximate optimal dosing, or they may not—there is simply no validated human PK data from which to derive principled dosing schedules.
Half-Life Extension Strategies: DAC, PEGylation, and Analogs
The pharmaceutical industry has developed several strategies to extend the half-lives of therapeutically promising peptides. Understanding these strategies clarifies why CJC-1295 with DAC behaves so differently from CJC-1295 without DAC, and why the GLP-1 receptor agonists have weekly dosing schedules while native GLP-1 has a 2-minute half-life.
Plain English
Pharmaceutical companies have developed tricks to make short-lived peptides last longer—attaching fatty acids (like semaglutide’s C18 chain), PEG molecules, or albumin-binding groups. These modifications turn daily injections into weekly ones by slowing how fast the body clears the compound.
Drug Affinity Complex (DAC) Technology
DAC technology attaches a reactive maleimide-dPEG acid moiety to the peptide. After injection, this group covalently binds to a cysteine residue on serum albumin—the most abundant protein in blood plasma. Albumin has a half-life of approximately 19 days, and binding to albumin shields the attached peptide from plasma peptidases and renal filtration, dramatically extending the peptide’s effective half-life. CJC-1295 with DAC achieves a half-life of 6–8 days through this mechanism—compared to approximately 30 minutes for the identical peptide sequence without DAC.
The pharmacological implications of DAC attachment go beyond half-life extension. A compound permanently bound to albumin has different receptor access than a freely circulating peptide—it may need to dissociate from albumin to interact with receptors, or may interact via a ternary complex. The sustained GH elevation from CJC-1295 with DAC compared to the pulsatile GH pattern from CJC-1295 (no DAC) has different physiological implications, including greater potential for receptor desensitization with the DAC form.
Fatty Acid Conjugation (Semaglutide, Tirzepatide)
Semaglutide has a C18 fatty diacid chain attached to its peptide backbone, which enables non-covalent albumin binding—similar in principle to DAC but reversible, so the peptide can detach from albumin, interact with receptors, and re-bind. This fatty acid modification, combined with substitutions that resist DPP-IV degradation, produces semaglutide’s approximately 7-day half-life from native GLP-1’s 2 minutes. The modification is precisely engineered: too little albumin binding produces a shorter half-life; too much may impair receptor binding.
PEGylation
PEGylation—attaching chains of polyethylene glycol to a peptide—increases molecular size and creates a hydrophilic shield around the peptide that reduces peptidase accessibility and renal filtration. It is used for several approved biologics. The tradeoffs include potential reduction in receptor binding affinity (the PEG chains can partially obstruct the binding interface) and altered immunogenicity. PEGylation is not used in any of the compounds currently covered on Peptidings but is relevant context for understanding the range of strategies in the field.
Frequently Asked Questions
If a peptide has a short half-life, does that mean it doesn’t work?
Not at all. Half-life determines duration of plasma exposure, not biological effect duration. Many signaling peptides produce effects that outlast their plasma half-life by orders of magnitude—because the downstream signaling cascades they trigger, the gene expression changes they induce, or the cellular states they modify persist long after the peptide is cleared. Insulin has a plasma half-life of about 5 minutes but produces metabolic effects lasting hours. VIP’s immunomodulatory effects observed in the RA clinical trial were produced with brief infusions. The pharmacological question is whether the receptor engagement during the plasma exposure window is sufficient to trigger the desired downstream effects.
What is the difference between CJC-1295 with and without DAC?
They are the same peptide sequence with one critical structural difference: CJC-1295 with DAC has a maleimide-dPEG acid attachment that causes it to covalently bind to serum albumin after injection, extending its half-life from approximately 30 minutes to 6–8 days. This produces continuously elevated GHRH receptor stimulation rather than pulsatile stimulation. CJC-1295 (no DAC) produces a brief GH pulse per injection; CJC-1295 with DAC produces sustained GHRH receptor engagement for nearly a week. The sustained pattern carries different receptor desensitization risks and different downstream GH secretion profiles. They are pharmacologically distinct compounds, not interchangeable doses of the same thing. See the individual compound articles for full detail.
How do I know what dosing interval to use for a compound without published human PK data?
Honestly, you often cannot derive a principled dosing interval without human PK data—which is one of the fundamental evidence gaps in research peptide use. What you can do: look at the published preclinical dosing schedule (how often was the compound administered in animal studies that showed efficacy?), check whether any clinical trials included dosing schedule information, and note whether the community convention has any pharmacological rationale behind it. For compounds without human PK data, the appropriate epistemic stance is that the dosing schedule is an educated estimate rather than an evidence-derived parameter.
Does semaglutide’s 7-day half-life mean it is always active for 7 days after injection?
Yes, in the sense that plasma concentrations persist for approximately 5 half-lives (~5 weeks) after a single injection before being functionally eliminated. In the sense of active GLP-1 receptor engagement, the concentration is highest in the first 1–3 days after injection and declines thereafter. The practical implication of the 7-day half-life is that once-weekly dosing maintains plasma concentrations above the minimum effective threshold throughout the dosing interval—reaching steady state after approximately 4–5 weeks of weekly dosing. If a dose is missed, the relatively slow decline means plasma concentrations do not drop precipitously in the first day or two, which is why the once-weekly dosing schedule is clinically practical.